Rituximab

Last updated

Rituximab
Rituximab.png
Monoclonal antibody
Type Whole antibody
Source Chimeric (mouse/human)
Target CD20
Clinical data
Trade names Rituxan, Mabthera, Mabthera SC, others
Biosimilars rituximab-abbs, [1] rituximab-pvvr, [2] rituximab-arrx, [3] Riabni, [3] Rixathon, [4] Riximyo, [5] Ruxience, [2] Truxima [1]
AHFS/Drugs.com Monograph
MedlinePlus a607038
License data
Pregnancy
category
Routes of
administration 		Intravenous
Drug class Monoclonal antibody
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability 100% (IV)
Elimination half-life 30 to 400 hours (varies by dose and length of treatment)
Excretion Uncertain: may undergo phagocytosis and catabolism in RES
Identifiers
CAS Number
DrugBank
ChemSpider
  • none
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard 100.224.382 OOjs UI icon edit-ltr-progressive.svg
Chemical and physical data
Formula C6416H9874N1688O1987S44
Molar mass 143860.04 g·mol−1
 X mark.svgNYes check.svgY  (what is this?)    (verify)

Rituximab, sold under the brand name Rituxan among others, is a monoclonal antibody medication used to treat certain autoimmune diseases and types of cancer. [15] It is used for non-Hodgkin lymphoma, chronic lymphocytic leukemia (in children and adults, but not recommended in elderly patients), rheumatoid arthritis, granulomatosis with polyangiitis, idiopathic thrombocytopenic purpura, pemphigus vulgaris, myasthenia gravis and Epstein–Barr virus-positive mucocutaneous ulcers. [15] [16] [17] [18] It is given by slow intravenous infusion (injected slowly through an IV line). [15] Biosimilars of Rituxan include Blitzima, Riabni, Ritemvia, Rituenza (F.K.A. Tuxella), Rixathon, Ruxience, and Truxima. [19] [20]

Contents

Common side effects which often occur within two hours of the medication being given include rash, itchiness, low blood pressure, and shortness of breath. Infections are also common. [15]

Severe side effects include reactivation of hepatitis B in those previously infected, progressive multifocal leukoencephalopathy, toxic epidermal necrolysis, and death. [15] [21] It is unclear if use during pregnancy is safe for the developing fetus or newborn baby, [6] [15] but it is not proven harmful.

Rituximab is a chimeric monoclonal antibody against the protein CD20, which is primarily found on the surface of immune system B cells. [22] When it binds to this protein it triggers cell death. [15]

Rituximab was approved for medical use in 1997. [22] It is on the World Health Organization's List of Essential Medicines. [23] Rituximab is co-marketed by Biogen and Genentech in the U.S., by Hoffmann-La Roche in Canada and the European Union, Chugai Pharmaceuticals, Zenyaku Kogyo in Japan and AryoGen in Iran. [24]

Medical uses

Rituximab is a chimeric monoclonal antibody targeted against CD20, a surface antigen present on B cells. It acts by depleting normal as well as pathogenic B cells while sparing plasma cells and hematopoietic stem cells, which do not express the CD20 surface antigen. [25]

In the United States, rituximab is indicated to treat:

  1. non-Hodgkin lymphoma (NHL) [13]
  2. chronic lymphocytic leukemia (CLL) [13]
  3. rheumatoid arthritis having inadequate response to one or more TNF inhibitors [13]
  4. vasculitides such as granulomatosis with polyangiitis and microscopic polyangiitis [13]
  5. moderate to severe pemphigus vulgaris [13]
  6. in combination with chemotherapy for children (≥ 6 months to < 18 years) with previously untreated, advanced stage, CD20-positive diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), Burkitt-like lymphoma (BLL), or mature acute B-cell leukemia (B-AL). [26]

Blood cancers

Rituximab is used to treat cancers of the white blood system such as leukemias and lymphomas, including non-Hodgkin's lymphoma, chronic lymphocytic leukemia, and nodular lymphocyte predominant Hodgkin's lymphoma. [27] [28] This also includes Waldenström's macroglobulinemia, a type of NHL. [15] Rituximab in combination with hyaluronidase human, sold under the brand names MabThera SC and Rituxan Hycela, [29] is used to treat follicular lymphoma, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia. [29] It is used in combination with fludarabine and cyclophosphamide to treat previously untreated and previously treated CD20-positive chronic lymphocytic leukemia. [13]

Autoimmune diseases

Rituximab has been shown to be an effective rheumatoid arthritis treatment in three randomised controlled trials and is now licensed for use in refractory rheumatoid disease. [30] In the United States, it has been FDA approved for use in combination with methotrexate for reducing signs and symptoms in adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more anti-TNF-alpha therapy. In the European Union, the license is slightly more restrictive: it is licensed for use in combination with methotrexate in patients with severe active RA who have had an inadequate response to one or more anti-TNF therapy. [31]

There is some evidence for efficacy, but not necessarily safety, in a range of other autoimmune diseases, and rituximab is widely used off-label to treat difficult cases of multiple sclerosis, [32] [33] systemic lupus erythematosus, chronic inflammatory demyelinating polyneuropathy and autoimmune anemias. [34] The most dangerous, although among the most rare, side effect is progressive multifocal leukoencephalopathy (PML) infection, which is usually fatal; however, only a very small number of cases have been recorded occurring in autoimmune diseases. [34] [35]

Other autoimmune diseases that have been treated with rituximab include autoimmune hemolytic anemia, pure red cell aplasia, thrombotic thrombocytopenic purpura (TTP), [36] idiopathic thrombocytopenic purpura (ITP), [37] [38] Evans syndrome, [39] vasculitis (e.g., granulomatosis with polyangiitis), bullous skin disorders (for example, pemphigus, pemphigoid—with very encouraging results of approximately 85% rapid recovery in pemphigus, according to a 2006 study), [40] type 1 diabetes mellitus, Sjögren syndrome, anti-NMDA receptor encephalitis and Devic's disease(Anti-AQP4 disease, MOG antibody disease), [41] Graves' ophthalmopathy, [42] autoimmune pancreatitis, [43] Opsoclonus myoclonus syndrome (OMS), [44] and IgG4-related disease. [45] There is some evidence that it is ineffective in treating IgA-mediated autoimmune diseases. [46]

Adverse events

Serious adverse events, which can cause death and disability, include: [13] [15]

Two patients with systemic lupus erythematosus died of progressive multifocal leukoencephalopathy (PML) after being treated with rituximab. PML is caused by activation of JC virus, a common virus in the brain which is usually latent. Reactivation of the JC virus usually results in death or severe brain damage. [52]

At least one patient with rheumatoid arthritis developed PML after treatment with rituximab. [53]

Rituximab has been reported as a possible cofactor in a chronic hepatitis E infection in a person with lymphoma. Hepatitis E infection is normally an acute infection, suggesting the drug in combination with lymphoma may have weakened the body's immune response to the virus. [54]

A major concern with continuous rituximab treatment is the difficulty to induce a proper vaccine response. [55] This was brought into focus during the COVID-19 pandemic, where persons with multiple sclerosis and rituximab treatment had higher risk of severe COVID-19. [56] In persons with rituximab treatment for multiple sclerosis, 9 of 10 patients with B cell counts of 40/µL or more developed protective levels of antibodies after vaccination with tozinameran. [57]

Mechanisms of action

Rituximab mechanisms of action; the three major independent mechanisms are (1) antibody dependent cellular cytotoxicity (ADCC), (2) complement mediated cytotoxicity (CMC), and (3) apoptosis; subset panel illustrates a schematic view of CD20 structure and rituximab. Rituximab mechanisms of action.jpg
Rituximab mechanisms of action; the three major independent mechanisms are (1) antibody dependent cellular cytotoxicity (ADCC), (2) complement mediated cytotoxicity (CMC), and (3) apoptosis; subset panel illustrates a schematic view of CD20 structure and rituximab.
Rituximab binding to CD20. The CD20 proteins are sticking out of the cell membrane, and rituximab, the Y-shaped antibody, is binding to the CD20 proteins. Rituxan in action.jpg
Rituximab binding to CD20. The CD20 proteins are sticking out of the cell membrane, and rituximab, the Y-shaped antibody, is binding to the CD20 proteins.

The antibody binds to the cell surface protein CD20. CD20 is widely expressed on B cells, from early pre-B cells to later in differentiation, but it is absent on terminally differentiated plasma cells. Although the function of CD20 is unknown, it may play a role in Ca2+ influx across plasma membranes, maintaining intracellular Ca2+ concentration and allowing activation of B cells.

Rituximab is relatively ineffective in elimination of cells with low CD20 cell-surface levels. [59] It tends to stick to one side of B cells, where CD20 is, forming a cap and drawing proteins over to that side. The presence of the cap changes the effectiveness of natural killer (NK) cells in destroying these B cells. When an NK cell latched onto the cap, it had an 80% success rate at killing the cell. In contrast, when the B cell lacked this asymmetric protein cluster, it was killed only 40% of the time. [60]

The following effects have been found: [61]

The combined effect results in the elimination of B cells (including the cancerous ones) from the body, allowing a new population of healthy B cells to develop from lymphoid stem cells.

Rituximab binds to amino acids 170–173 and 182–185 on CD20, which are physically close to each other as a result of a disulfide bond between amino acids 167 and 183. [63]

History

Rituximab was developed by IDEC Pharmaceuticals under the name IDEC-C2B8. The U.S. patent for the drug was issued in 1998 and expired in 2015. [64]

Based on its safety and effectiveness in clinical trials, [65] rituximab was approved by the U.S. Food and Drug Administration in 1997 to treat B-cell non-Hodgkin lymphomas resistant to other chemotherapy regimens. [66] Rituximab, in combination with CHOP chemotherapy, is superior to CHOP alone in the treatment of diffuse large B-cell lymphoma and many other B-cell lymphomas. [67] In 2010, it was approved by the European Commission for maintenance treatment after initial treatment of follicular lymphoma. [68]

It is on the World Health Organization's List of Essential Medicines. [23]

In 2014, Genentech reclassified rituxan as a specialty drug, a class of drugs that are only available through specialty distributors in the US. [69] Because wholesalers discounts and rebates no longer apply, hospitals would pay more. [69]

Originally available for intravenous injection (e.g. over 2.5 hrs), in 2016, it gained EU approval in a formulation for subcutaneous injection for B-cell CLL/lymphoma (CLL). [70]

Society and culture

Economics

Patents on the drug expired in Europe in February 2013, and in the US in September 2016.[ failed verification ] [71] By November 2018, several biosimilars had been approved in the US, India, the European Union, Switzerland, Japan and Australia. The US FDA approved Truxima (rituximab-abbs) in 2018, Ruxience (rituximab-pvvr) in 2019 and Riabni (rituximab-arrx) in 2020. The Riabni is about $3600 per 500 mg, wholesale, list. Truxima is about the same price as Riabni - 10% less than Rituxan, while Ruxience is 24% less than Rituxan. [72] [71] [73] [74] [75]

Research

Chronic fatigue syndrome

Rituximab did not improve symptoms in patients with chronic fatigue syndrome in a trial published in 2019. [76] [77] Twenty-two percent of participants had serious events. [76] This potential use was investigated after improvements in chronic fatigue syndrome was seen in two cancer patients treated with rituximab. [78]

Intrathecal

For CNS diseases, rituximab could be administered intrathecally and this possibility is under study. [79]

Other anti-CD20 monoclonals

The efficacy and success of rituximab has led to some other anti-CD20 monoclonal antibodies being developed:

Related Research Articles

<span class="mw-page-title-main">Infliximab</span> Biopharmaceutical drug for autommune disorders

Infliximab, a chimeric monoclonal antibody, sold under the brand name Remicade among others, is a medication used to treat a number of autoimmune diseases. This includes Crohn's disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriasis, psoriatic arthritis, and Behçet's disease. It is given by slow injection into a vein, typically at six- to eight-week intervals.

<span class="mw-page-title-main">Cryoglobulinemia</span> Medical condition

Cryoglobulinemia is a medical condition in which the blood contains large amounts of pathological cold sensitive antibodies called cryoglobulins – proteins that become insoluble at reduced temperatures. This should be contrasted with cold agglutinins, which cause agglutination of red blood cells.

<span class="mw-page-title-main">Cancer immunotherapy</span> Artificial stimulation of the immune system to treat cancer

Cancer immunotherapy (immuno-oncotherapy) is the stimulation of the immune system to treat cancer, improving the immune system's natural ability to fight the disease. It is an application of the fundamental research of cancer immunology and a growing subspecialty of oncology.

<span class="mw-page-title-main">Ibritumomab tiuxetan</span> Radioimmunotherapy treatment

Ibritumomab tiuxetan, sold under the trade name Zevalin, is a monoclonal antibody radioimmunotherapy treatment for non-Hodgkin's lymphoma. The drug uses the monoclonal mouse IgG1 antibody ibritumomab in conjunction with the chelator tiuxetan, to which a radioactive isotope is added. Tiuxetan is a modified version of DTPA whose carbon backbone contains an isothiocyanatobenzyl and a methyl group.

<span class="mw-page-title-main">Alemtuzumab</span> Medication

Alemtuzumab, sold under the brand names Campath and Lemtrada among others, is a medication used to treat chronic lymphocytic leukemia and multiple sclerosis. In chronic lymphocytic leukemia, it has been used as both a first line and second line treatment. It is given by injection into a vein.

<span class="mw-page-title-main">Biological therapy for inflammatory bowel disease</span>

Biological therapy, the use of medications called biopharmaceuticals or biologics that are tailored to specifically target an immune or genetic mediator of disease, plays a major role in the treatment of inflammatory bowel disease. Even for diseases of unknown cause, molecules that are involved in the disease process have been identified, and can be targeted for biological therapy. Many of these molecules, which are mainly cytokines, are directly involved in the immune system. Biological therapy has found a niche in the management of cancer, autoimmune diseases, and diseases of unknown cause that result in symptoms due to immune related mechanisms.

<span class="mw-page-title-main">CD20</span> Mammalian protein found in Homo sapiens

B-lymphocyte antigen CD20 or CD20 is expressed on the surface of all B-cells beginning at the pro-B phase and progressively increasing in concentration until maturity.

Biological response modifiers (BRMs) are substances that modify immune responses. They can be endogenous or exogenous, and they can either enhance an immune response or suppress it. Some of these substances arouse the body's response to an infection, and others can keep the response from becoming excessive. Thus they serve as immunomodulators in immunotherapy, which can be helpful in treating cancer and in treating autoimmune diseases, such as some kinds of arthritis and dermatitis. Most BRMs are biopharmaceuticals (biologics), including monoclonal antibodies, interleukin 2, interferons, and various types of colony-stimulating factors. "Immunotherapy makes use of BRMs to enhance the activity of the immune system to increase the body's natural defense mechanisms against cancer", whereas BRMs for rheumatoid arthritis aim to reduce inflammation.

<span class="mw-page-title-main">Belimumab</span> Pharmaceutical drug

Belimumab, sold under the brand name Benlysta, is a human monoclonal antibody that inhibits B-cell activating factor (BAFF), also known as B-lymphocyte stimulator (BLyS). It is approved in the United States and Canada, and the European Union to treat systemic lupus erythematosus and lupus nephritis.

Ocrelizumab, sold under the brand name Ocrevus, is a medication used for the treatment of multiple sclerosis (MS). It is a humanized anti-CD20 monoclonal antibody. It targets CD20 marker on B lymphocytes and is an immunosuppressive drug. Ocrelizumab binds to an epitope that overlaps with the epitope to which rituximab binds.

<span class="mw-page-title-main">Ofatumumab</span> Medication

Ofatumumab is a fully human monoclonal antibody to CD20, which appears to provide rapid B-cell depletion. Under the brand name Kesimpta, it is approved for the treatment of multiple sclerosis in the United States as well as in the European Union and other regions. Under the brand name Arzerra, it is approved for the treatment of certain types of chronic lymphocytic leukemia (CLL) in the United States. It is sold by Novartis under license from Genmab.

Obinutuzumab, sold under the brand name Gazyva among others, is a humanized anti-CD20 monoclonal antibody used as a treatment for cancer. It was originated by GlycArt Biotechnology AG and developed by Roche.

Atacicept is a recombinant fusion protein designed to inhibit B cells, thereby suppressing autoimmune disease. The designer protein combines the binding site for two cytokines that regulate maturation, function, and survival of B cells - B-lymphocyte stimulator (BLyS) and A proliferation-inducing ligand (APRIL), with the constant region of immunoglobin. Atacicept blocks activation of B cells by the tumor necrosis factor receptor superfamily member 13B, a transmembrane receptor protein found predominantly on the surface of B cells. Like the monoclonal antibody belimumab, atacicept blocks the binding of BLyS, but it also blocks APRIL. Binding of these TACI ligands induces proliferation, activation, and longevity of B cells and thus their production of autoantibodies. Atacicept is thought to selectively impair mature B cells and plasma cells with less impact on progenitor cells and memory B cells.

Gene expression profiling has revealed that diffuse large B-cell lymphoma (DLBCL) is composed of at least 3 different sub-groups, each having distinct oncogenic mechanisms that respond to therapies in different ways. Germinal Center B-Cell like (GCB) DLBCLs appear to arise from normal germinal center B cells, while Activated B-cell like (ABC) DLBCLs are thought to arise from postgerminal center B cells that are arrested during plasmacytic differentiation. The differences in gene expression between GCB DLBCL and ABC DLBCL are as vast as the differences between distinct types of leukemia, but these conditions have historically been grouped together and treated as the same disease.

<span class="mw-page-title-main">Ibrutinib</span> Medication used in cancer treatment

Ibrutinib, sold under the brand name Imbruvica among others, is a small molecule drug that inhibits B-cell proliferation and survival by irreversibly binding the protein Bruton's tyrosine kinase (BTK). Blocking BTK inhibits the B-cell receptor pathway, which is often aberrantly active in B cell cancers. Ibrutinib is therefore used to treat such cancers, including mantle cell lymphoma, chronic lymphocytic leukemia, and Waldenström's macroglobulinemia. Ibrutinib also binds to C-terminal Src Kinases. These are off-target receptors for the BTK inhibitor. Ibrutinib binds to these receptors and inhibits the kinase from promoting cell differentiation and growth. This leads to many different side effects like left atrial enlargement and atrial fibrillation during the treatment of Chronic Lymphocytic Leukemia.

Ocaratuzumab is a humanized monoclonal antibody designed for the treatment of cancer and autoimmune disorders. The antibody is engineered for enhanced affinity to the CD20 antigen on B-lymphocytes, increased antibody-dependent cell-mediated cytotoxicity (ADCC), and for improved treatment of low-affinity FcγRIIIa allotypes.

Celltrion, Inc. is a biopharmaceutical company headquartered in Incheon, South Korea. Celltrion Healthcare conducts worldwide marketing, sales, and distribution of biological medicines developed by Celltrion. Celltrion's founder, Seo Jung-jin, is the richest person in South Korea.

David G. Maloney is an oncologist and researcher at Fred Hutchinson Cancer Research Center and the University of Washington who specializes in developing targeted immunotherapies for the treatment of blood cancers.

Otilimab is a fully human antibody which has been developed by the biotechnology company MorphoSys. It can also be referred to as HuCAL antibody, HuCAL standing for Human Combinatorial Antibody Library and being a technology used to generate monoclonal antibodies. Otilimab is directed against the granulocyte-macrophage colony stimulating factor (GM-CSF), a monomeric glycoprotein functioning as a cytokine promoting both proliferation and activation of macrophages and neutrophils.

Passive antibody therapy, also called serum therapy, is a subtype of passive immunotherapy that administers antibodies to target and kill pathogens or cancer cells. It is designed to draw support from foreign antibodies that are donated from a person, extracted from animals, or made in the laboratory to elicit an immune response instead of relying on the innate immune system to fight disease. It has a long history from the 18th century for treating infectious diseases and is now a common cancer treatment. The mechanism of actions include: antagonistic and agonistic reaction, complement-dependent cytotoxicity (CDC), and antibody-dependent cellular cytotoxicity (ADCC).

References

  1. 1 2 3 "Truxima- rituximab-abbs injection solution". DailyMed. Retrieved 26 March 2021.
  2. 1 2 3 "Ruxience- rituximab-pvvr injection solution". DailyMed. Retrieved 26 March 2021.
  3. 1 2 3 "Riabni- rituximab-arrx injection solution". DailyMed. Retrieved 26 March 2021.
  4. ↑ "Rixathon EPAR". European Medicines Agency. 15 June 2017. Retrieved 7 January 2024.
  5. ↑ "Summary Basis of Decision (SBD) for Riximyo". Health Canada. 23 October 2014. Retrieved 29 May 2022.
  6. 1 2 "Rituximab Use During Pregnancy". Drugs.com. 16 December 2019. Retrieved 2 February 2020.
  7. ↑ Rituximab (rch) (CAS registry number: 174722-31-7) Archived 30 November 2015 at the Wayback Machine
  8. ↑ Australian Product Information. MabThera SC (rituximab) Archived 13 May 2021 at the Wayback Machine
  9. ↑ "Health product highlights 2021: Annexes of products approved in 2021". Health Canada . 3 August 2022. Retrieved 25 March 2024.
  10. ↑ "MabThera 100 mg Concentrate for Solution for Infusion - Summary of Product Characteristics (SmPC)". (emc). 13 March 2021. Retrieved 26 March 2021.
  11. ↑ "MabThera 1400 mg Solution for Subcutaneous Injection - Summary of Product Characteristics (SmPC)". (emc). 13 March 2021. Retrieved 26 March 2021.
  12. ↑ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA . Retrieved 22 October 2023.
  13. 1 2 3 4 5 6 7 8 "Rituxan- rituximab injection, solution". DailyMed. 6 November 2019. Retrieved 2 February 2020.
  14. ↑ "MabThera EPAR". European Medicines Agency. 17 September 2018. Retrieved 8 September 2021.
  15. 1 2 3 4 5 6 7 8 9 "Rituximab". The American Society of Health-System Pharmacists. Archived from the original on 27 March 2016. Retrieved 8 December 2016.
  16. ↑ Tandan R, Hehir MK, Waheed W, Howard DB (August 2017). "Rituximab treatment of myasthenia gravis: A systematic review". Muscle & Nerve. 56 (2): 185–196. doi:10.1002/mus.25597. PMID   28164324. S2CID   19504332.
  17. ↑ Singer O, McCune WJ (May 2017). "Update on maintenance therapy for granulomatosis with polyangiitis and microscopic polyangiitis". Current Opinion in Rheumatology. 29 (3): 248–253. doi:10.1097/BOR.0000000000000382. PMID   28306595. S2CID   35805200.
  18. ↑ Dojcinov SD, Fend F, Quintanilla-Martinez L (March 2018). "EBV-Positive Lymphoproliferations of B- T- and NK-Cell Derivation in Non-Immunocompromised Hosts". Pathogens. 7 (1): 28. doi: 10.3390/pathogens7010028 . PMC   5874754 . PMID   29518976.
  19. ↑ "Rituximab Biosimilars Shown to Be Safe and Effective". www.medscape.com. Archived from the original on 15 March 2018. Retrieved 29 November 2017.
  20. ↑ "rituximab | Ligand page | IUPHAR/BPS Guide to PHARMACOLOGY". www.guidetopharmacology.org.
  21. ↑ "Boxed Warning and new recommendations to decrease risk of hepatitis B reactivation with the immune-suppressing and anti-cancer drugs Arzerra (ofatumumab) and Rituxan (rituximab)". U.S. Food and Drug Administration (FDA). 29 February 2016. Retrieved 2 February 2020.
  22. 1 2 Bosch X, Ramos-Casals M, Khamashta MA (2013). Drugs Targeting B-Cells in Autoimmune Diseases. Springer Science & Business Media. pp. 1–4. ISBN   9783034807067. Archived from the original on 5 November 2017.
  23. 1 2 World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl: 10665/325771 . WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
  24. ↑ "FDA Approves Rituxan Plus Chemotherapy for the Most Common Type of Adult Leukemia" (Press release). Biogen.
  25. ↑ De A, Ansari A, Sharma N, Sarda A (2017). "Shifting Focus in the Therapeutics of Immunobullous Disease". Indian Journal of Dermatology. 62 (3): 282–290. doi: 10.4103/ijd.IJD_199_17 (inactive 31 January 2024). PMC   5448263 . PMID   28584371.{{cite journal}}: CS1 maint: DOI inactive as of January 2024 (link)
  26. ↑ "FDA approves rituximab plus chemotherapy for pediatric cancer indicati". U.S. Food and Drug Administration. 3 December 2021. Retrieved 4 December 2021.PD-icon.svg This article incorporates text from this source, which is in the public domain .
  27. ↑ Saini KS, Azim HA, Cocorocchio E, Vanazzi A, Saini ML, Raviele PR, et al. (August 2011). "Rituximab in Hodgkin lymphoma: is the target always a hit?". Cancer Treatment Reviews. 37 (5): 385–390. doi:10.1016/j.ctrv.2010.11.005. PMID   21183282.
  28. ↑ Eichenauer DA, Engert A (December 2017). "Nodular lymphocyte-predominant Hodgkin lymphoma: a unique disease deserving unique management". Hematology. American Society of Hematology. Education Program. 2017 (1): 324–328. doi:10.1182/asheducation-2017.1.324. PMC   6142570 . PMID   29222274.
  29. 1 2 "Rituxan Hycela- rituximab and hyaluronidase injection, solution". DailyMed. 3 December 2019. Retrieved 2 February 2020.
  30. ↑ Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, et al. (June 2004). "Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis". The New England Journal of Medicine. 350 (25): 2572–2581. doi: 10.1056/NEJMoa032534 . PMID   15201414.
  31. ↑ Tak PP, Kalden JR (May 2011). "Advances in rheumatology: new targeted therapeutics". Arthritis Research & Therapy. 13 (Suppl 1): S5. doi: 10.1186/1478-6354-13-S1-S5 . PMC   3123966 . PMID   21624184.
  32. ↑ McGinley MP, Moss BP, Cohen JA (January 2017). "Safety of monoclonal antibodies for the treatment of multiple sclerosis". Expert Opinion on Drug Safety. 16 (1): 89–100. doi:10.1080/14740338.2017.1250881. PMID   27756172. S2CID   36762194.
  33. ↑ He D, Guo R, Zhang F, Zhang C, Dong S, Zhou H (December 2013). "Rituximab for relapsing-remitting multiple sclerosis". The Cochrane Database of Systematic Reviews (12): CD009130. doi:10.1002/14651858.CD009130.pub3. PMID   24310855.
  34. 1 2 Paul M (20 May 2009). "Popular Cancer Drug Linked to Often Fatal 'Brain Eating' Virus". Northwestern University News and Information. Archived from the original on 29 May 2010. Retrieved 22 May 2009.
  35. ↑ "FDA Warns of Safety Concern Regarding Rituxan in New Patient Population". U.S. Food and Drug Administration (FDA) (Press release). 18 December 2006. Archived from the original on 13 May 2009. Retrieved 29 April 2013.
  36. ↑ Froissart A, Veyradier A, Hié M, Benhamou Y, Coppo P (November 2015). "Rituximab in autoimmune thrombotic thrombocytopenic purpura: A success story". European Journal of Internal Medicine. 26 (9): 659–665. doi: 10.1016/j.ejim.2015.07.021 . PMID   26293834.
  37. ↑ Braendstrup P, Bjerrum OW, Nielsen OJ, Jensen BA, Clausen NT, Hansen PB, et al. (April 2005). "Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura". American Journal of Hematology. 78 (4): 275–280. doi: 10.1002/ajh.20276 . PMID   15795920. S2CID   42218074.
  38. ↑ Patel V, Mihatov N, Cooper N, Stasi R, Cunningham-Rundles S, Bussel JB (2007). "Long-term responses seen with rituximab in patients with ITP" (PDF). Community Oncology. 4 (2): 107. doi:10.1016/s1548-5315(11)70061-4. Archived from the original (PDF) on 29 September 2007. Retrieved 18 April 2007.
  39. ↑ Shanafelt TD, Madueme HL, Wolf RC, Tefferi A (November 2003). "Rituximab for immune cytopenia in adults: idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, and Evans syndrome". Mayo Clinic Proceedings. 78 (11): 1340–1346. doi:10.4065/78.11.1340. PMID   14601692.
  40. ↑ Ahmed AR, Spigelman Z, Cavacini LA, Posner MR (October 2006). "Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin". The New England Journal of Medicine. 355 (17): 1772–1779. doi: 10.1056/nejmoa062930 . PMID   17065638.
  41. ↑ Jacob A, Weinshenker BG, Violich I, McLinskey N, Krupp L, Fox RJ, et al. (November 2008). "Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients". Archives of Neurology. 65 (11): 1443–1448. doi: 10.1001/archneur.65.11.noc80069 . PMID   18779415.
  42. ↑ "Rituximab Treatment of Patients with Severe, Corticosteroid-Resistant Thyroid-Associated Ophthalmopathy". Archived from the original on 22 August 2017. Retrieved 19 October 2011.
  43. ↑ Hart PA, Chari ST (11 June 2013). "Immunomodulators and Rituximab in the Management of Autoimmune Pancreatitis". Pancreapedia. doi: 10.3998/panc.2013.20 .
  44. ↑ Pranzatelli MR, Tate ED, Travelstead AL, Longee D (January 2005). "Immunologic and clinical responses to rituximab in a child with opsoclonus-myoclonus syndrome". Pediatrics. 115 (1): e115–e119. doi: 10.1542/peds.2004-0845 . PMID   15601813.
  45. ↑ Khosroshahi A, Wallace ZS, Crowe JL, Akamizu T, Azumi A, Carruthers MN, et al. (July 2015). "International Consensus Guidance Statement on the Management and Treatment of IgG4-Related Disease". Arthritis & Rheumatology. 67 (7): 1688–1699. doi:10.1002/art.39132. PMID   25809420. S2CID   39750214.
  46. ↑ He Y, Shimoda M, Ono Y, Villalobos IB, Mitra A, Konia T, et al. (June 2015). "Persistence of Autoreactive IgA-Secreting B Cells Despite Multiple Immunosuppressive Medications Including Rituximab". JAMA Dermatology. 151 (6): 646–650. doi: 10.1001/jamadermatol.2015.59 . PMID   25901938.
  47. ↑ Kyriakidis I, Mantadakis E, Stiakaki E, Groll AH, Tragiannidis A (October 2022). "Infectious Complications of Targeted Therapies in Children with Leukemias and Lymphomas". Cancers. 14 (20): 5022. doi: 10.3390/cancers14205022 . PMC   9599435 . PMID   36291806.
  48. ↑ Molloy ES, Calabrese LH (September 2012). "Progressive multifocal leukoencephalopathy associated with immunosuppressive therapy in rheumatic diseases: evolving role of biologic therapies". Arthritis and Rheumatism. 64 (9): 3043–3051. doi:10.1002/art.34468. PMID   22422012.
  49. ↑ Grammatikos A, Donati M, Johnston SL, Gompels MM (30 August 2021). "Peripheral B Cell Deficiency and Predisposition to Viral Infections: The Paradigm of Immune Deficiencies". Frontiers in Immunology. 12: 731643. doi: 10.3389/fimmu.2021.731643 . PMC   8435594 . PMID   34527001.
  50. ↑ Burton C, Kaczmarski R, Jan-Mohamed R (June 2003). "Interstitial pneumonitis related to rituximab therapy". The New England Journal of Medicine. 348 (26): 2690–1, discussion 2690–1. doi:10.1056/NEJM200306263482619. PMID   12826649.
  51. ↑ "Reports of Bowel Obstruction and Perforation with RITUXAN (rituximab)" (PDF). Roche Canada. 10 November 2006. Archived from the original (PDF) on 27 March 2014.
  52. ↑ "Rituximab (marketed as Rituxan) Information". U.S. Food and Drug Administration (FDA). 23 July 2015. Archived from the original on 15 November 2009. Retrieved 15 November 2009.
  53. ↑ "Rituximab, RA and PML" (PDF). U.S. Food and Drug Administration (FDA). Archived from the original (PDF) on 16 September 2008. Retrieved 14 September 2008.
  54. ↑ Kriston L, Härter M, Hölzel L (March 2009). "Challenges in reporting meta-analyses of diagnostic accuracy studies". Annals of Internal Medicine. 150 (6): 430. doi:10.7326/0003-4819-150-6-200903170-00025. PMID   19293085.
  55. ↑ Oren S, Mandelboim M, Braun-Moscovici Y, Paran D, Ablin J, Litinsky I, et al. (July 2008). "Vaccination against influenza in patients with rheumatoid arthritis: the effect of rituximab on the humoral response". Annals of the Rheumatic Diseases. 67 (7): 937–941. doi: 10.1136/ard.2007.077461 . PMID   17981914. S2CID   21878513.
  56. ↑ Spelman T, Forsberg L, McKay K, Glaser A, Hillert J (June 2022) [EPub July 2, 2021 (date first published online - nearly a year earlier)]. "Increased rate of hospitalisation for COVID-19 among rituximab-treated multiple sclerosis patients: A study of the Swedish multiple sclerosis registry". Multiple Sclerosis. 28 (7): 1051–1059. doi: 10.1177/13524585211026272 . PMID   34212816. S2CID   235710318.
  57. ↑ Tolf A, Wiberg A, Müller M, Nazir FH, Pavlovic I, Laurén I, et al. (May 2022). "Factors Associated With Serological Response to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Treated With Rituximab". JAMA Network Open. 5 (5): e2211497. doi:10.1001/jamanetworkopen.2022.11497. PMC   9096596 . PMID   35544139. S2CID   248695128.
  58. ↑ Seyfizadeh N, Seyfizadeh N, Hasenkamp J, Huerta-Yepez S (January 2016). "A molecular perspective on rituximab: A monoclonal antibody for B cell non Hodgkin lymphoma and other affections". Critical Reviews in Oncology/Hematology. 97: 275–290. doi:10.1016/j.critrevonc.2015.09.001. PMID   26443686.
  59. 1 2 Pavlasova G, Borsky M, Svobodova V, Oppelt J, Cerna K, Novotna J, et al. (September 2018). "Rituximab primarily targets an intra-clonal BCR signaling proficient CLL subpopulation characterized by high CD20 levels". Leukemia. 32 (9): 2028–2031. doi: 10.1038/s41375-018-0211-0 . PMID   30030508.
  60. ↑ Rudnicka D, Oszmiana A, Finch DK, Strickland I, Schofield DJ, Lowe DC, et al. (June 2013). "Rituximab causes a polarization of B cells that augments its therapeutic function in NK-cell-mediated antibody-dependent cellular cytotoxicity". Blood. 121 (23): 4694–4702. doi: 10.1182/blood-2013-02-482570 . PMID   23613524.
  61. ↑ Shaw T, Quan J, Totoritis MC (November 2003). "B cell therapy for rheumatoid arthritis: the rituximab (anti-CD20) experience". Annals of the Rheumatic Diseases. 62 (Suppl 2): ii55–ii59. doi:10.1136/ard.62.suppl_2.ii55. PMC   1766758 . PMID   14532151.
  62. 1 2 Borsky M, Hrabcakova V, Novotna J, Brychtova Y, Doubek M, Panovska A, et al. (December 2021). "Rituximab induces rapid blood repopulation by CLL cells mediated through their release from immune niches and complement exhaustion". Leukemia Research. 111: 106684. doi:10.1016/j.leukres.2021.106684. PMID   34438120.
  63. ↑ Binder M, Otto F, Mertelsmann R, Veelken H, Trepel M (September 2006). "The epitope recognized by rituximab". Blood. 108 (6): 1975–1978. doi: 10.1182/blood-2006-04-014639 . PMID   16705086.
  64. ↑ "Rituximab". go.drugbank.com. Archived from the original on 5 January 2014. Retrieved 14 March 2023.
  65. ↑ Maloney DG, Grillo-López AJ, White CA, Bodkin D, Schilder RJ, Neidhart JA, et al. (September 1997). "IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma". Blood. 90 (6): 2188–2195. doi: 10.1182/blood.V90.6.2188 . PMID   9310469.
  66. ↑ Scott SD (1998). "Rituximab: a new therapeutic monoclonal antibody for non-Hodgkin's lymphoma". Cancer Practice. 6 (3): 195–197. doi:10.1046/j.1523-5394.1998.006003195.x. PMID   9652253.
  67. ↑ Harrison's Principles of Internal Medicine, Longo et al. McGraw Hill Medical 2011 page 931
  68. ↑ "Roche Gets EC Nod for Follicular Lymphoma Maintenance Therapy". 29 October 2010. Archived from the original on 31 October 2010.
  69. 1 2 Saporito B (27 October 2014). "Hospitals Furious at Cancer-Drug Price Hikes". Time. Archived from the original on 20 October 2015. Retrieved 26 October 2015.
  70. ↑ "EU approves second indication for subcutaneous form of Roche's rituximab". Archived from the original on 7 June 2016. Retrieved 9 June 2016.
  71. 1 2 "Biosimilars of Rituximab". Generics and Biosimilars Initiative. 14 April 2017. Archived from the original on 31 March 2017. Retrieved 29 April 2017.
  72. ↑ "FDA approves first biosimilar for treatment of adult patients with non-Hodgkin's lymphoma". U.S. Food and Drug Administration (FDA) (Press release). 28 November 2018. Retrieved 11 November 2019.
  73. ↑ Lahiri D, Osterman C (2 November 2018). "Novartis abandons effort for U.S. approval of biosimilar rituximab". Reuters. Retrieved 3 November 2018.
  74. ↑ "Amgen Rituximab Biosimilar Gains FDA Approval". The Center For Biosimilars. 17 December 2020.
  75. ↑ "Teva, Celltrion Maintain Slender Discount to Rituxan". Center for Biosimilars. 4 May 2020. Retrieved 30 March 2024.
  76. 1 2 Fluge Ø, Rekeland IG, Lien K, Thürmer H, Borchgrevink PC, Schäfer C, et al. (May 2019). "B-Lymphocyte Depletion in Patients With Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial". Annals of Internal Medicine. 170 (9): 585–593. doi:10.7326/M18-1451. PMID   30934066. S2CID   91186383.
  77. ↑ Tucker ME (2 April 2019). "Rituximab Fails to Improve Symptoms in ME/CFS" . Medscape .
  78. ↑ Castro-Marrero J, Sáez-Francàs N, Santillo D, Alegre J (March 2017). "Treatment and management of chronic fatigue syndrome/myalgic encephalomyelitis: all roads lead to Rome". British Journal of Pharmacology. 174 (5): 345–369. doi:10.1111/bph.13702. PMC   5301046 . PMID   28052319.
  79. ↑ Bonnan M, Ferrari S, Bertandeau E, Demasles S, Krim E, Miquel M, et al. (2014). "Intrathecal rituximab therapy in multiple sclerosis: review of evidence supporting the need for future trials". Current Drug Targets. 15 (13): 1205–1214. doi:10.2174/1389450115666141029234644. PMID   25355180.
  80. ↑ "Genmab.com / HuMax-CD20 (ofatumumab)". Archived from the original on 11 September 2007. Retrieved 3 December 2007.
  81. ↑ "Fc-structure". Archived from the original on 10 November 2007. Retrieved 3 December 2007.
  82. ↑ Eccles SA (2001). "Monoclonal antibodies targeting cancer: 'magic bullets' or just the trigger?". Breast Cancer Research. 3 (2): 86–90. doi: 10.1186/bcr276 . PMC   138676 . PMID   11250751.
  83. ↑ Maverakis E, Kim K, Shimoda M, Gershwin ME, Patel F, Wilken R, et al. (February 2015). "Glycans in the immune system and The Altered Glycan Theory of Autoimmunity: a critical review". Journal of Autoimmunity. 57 (6): 1–13. doi:10.1016/j.jaut.2014.12.002. PMC   4340844 . PMID   25578468.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.